

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal (STA)

Nivolumab for treating advanced or metastatic renal cell carcinoma after anti-angiogenic therapy [ID853]

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Bristol-Myers Squibb (nivolumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Black Health Agency • British Kidney Patient Association • Cancer Black Care • Cancer Equality • Cancer 52 • Helen Rollason Cancer Charity • HAWC • Independent Cancer Patients Voice • James Whale Fund for Kidney Cancer • Kidney Cancer Support Network • Kidney Cancer UK • Kidney Research UK • Macmillan Cancer Support • Maggie's Centres • Marie Curie Cancer Care • Muslim Council of Britain • National Kidney Federation • Rarer Cancers Foundation • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus Cancer Care <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • British Association of Urological Nurses • British Association of Urological Surgeons • British Geriatrics Society • British Psychosocial Oncology Society • British Renal Society • Cancer Research UK 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Association of Renal Industries • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium • Welsh Kidney Patients Association • Welsh Urological Society <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Pfizer (axitinib) • Novartis Pharmaceuticals (everolimus) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Prostatic Diseases and Urologic Cancers Group • MRC Clinical Trials Unit • National Cancer Research Institute • National Cancer Research Network • National Institute for Health Research • The Institute of Cancer Research <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England

National Institute for Health and Care Excellence
 Provisional matrix for the technology appraisal of nivolumab for treating advanced or metastatic renal cell carcinoma after anti-angiogenic therapy [ID853]

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Renal Association • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for DGH Nephrologists • The Urology Foundation • UK Clinical Pharmacy Association • UK Health Forum • UK Renal Pharmacy Group • UK Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS City and Hackney CCG • NHS England • NHS Newham CCG • Welsh Government 	<ul style="list-style-type: none"> • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland;; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹Non-company consultees are invited to submit statements relevant to the group they are representing.